Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Directing the Clerk of the House of Representatives to make technical corrections in the enrollment of H.R. 2918.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2009 · fourth_quarter · 4A
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Source: Senate LDA
Directing the Clerk of the House of Representatives to make technical corrections in the enrollment of H.R. 2918.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Directing the Clerk of the House of Representatives to make technical corrections in the enrollment of H.R. 2918.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R.1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Pathway for Biosimilars Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Pathway for Biosimilars Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pathway for Biosimilars Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pathway for Biosimilars Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
Pathway for Biosimilars Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Early Treatment for HIV Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Early Treatment for HIV Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Early Treatment for HIV Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Early Treatment for HIV Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R.1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Comparative Effectiveness Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Comparative Effectiveness Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Comparative Effectiveness Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Comparative Effectiveness Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
America's Affordable Health Choices Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
America's Affordable Health Choices Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
America's Affordable Health Choices Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, the Medicare Home Infusion Therapy Coverage Act. Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. 4S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, the Medicare Home Infusion Therapy Coverage Act. Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. 4S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Food and Drug Administration Globalization Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Food and Drug Administration Globalization Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
Food and Drug Administration Globalization Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Food and Drug Administration Globalization Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Food and Drug Administration Globalization Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Patient-Centered Outcomes Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Patient-Centered Outcomes Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Patient-Centered Outcomes Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Patient-Centered Outcomes Research Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Affordable Health Choices Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Affordable Health Choices Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Affordable Health Choices Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, the Medicare Home Infusion Therapy Coverage Act. Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. 4S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Home Infusion Therapy Coverage Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Physician Payments Sunshine Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Physician Payments Sunshine Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Physician Payments Sunshine Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Physician Payments Sunshine Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
Medicare Prescription Drug Savings and Choice Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, the Medicare Home Infusion Therapy Coverage Act. Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. 4S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R.1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R.1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
Patent Reform Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
Pharmaceutical Market Access and Drug Safety Act of 2009
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2009 · fourth_quarter · Q4
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied to protect access to safe and affordable prescription drugs.
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1458/S. 565, Comprehensive Immunosuppresive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684/S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
H. Con. Res. 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. H.R. 3962, Affordable Health Care for America Act and H.R. 3590, Patient Protection & Affordable Care Act (Senate). Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232, and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to all for the importation of unsafe prescription drugs. H.R. 1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H. Con. Res. 191, Continuing Resolution. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied Members of Congress to ensure patient safety and access to prescription drugs. H.R. 3200/S. 1679, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/S. 726, Promoting Innovation and Access to Life-Saving Medicines Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 3974, Viral Hepatitis & Liver Cancer Control & Prevention Act. Lobbied for passage of legislation.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2009 · third_quarter · Q3
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
H. CON. RES 191, Continuing Resolution. Lobbied to ensure safety and access to prescription drugs. H.R. 3293, Labor Health and Human Services Appropriations bill. Lobbied to ensure safety and access to prescription drugs. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548 and 1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, the Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 3293, Labor, HHS Appropriations Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H. Con. Res 191, Continuing Resolution. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1298/ S. 525/ S.1232, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 3200/ S.1679/, Senate Finance Committee bill. Lobbied to improve the health care system and increase access to prescription drugs. H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity.
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007.Lobbied for passage of bills. S. 547, Drug Rebate Equalization Act of 2009. Lobbied against extending the Medicaid rebate to managed care organizations H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574/ S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied in support of early treatment of HIV/AIDS.
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2009 · second_quarter · Q2
NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. H.R. 1548, Pathway for Biosimilars Act. Lobbied Members of congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R.1427/ S. 726, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525, S. 1232 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. S. 982, Family Smoking Prevention and Tobacco Control Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 1213 and H.R. 2502, Patient-Centered Outcomes Research Act. Lobbied Members of Congress to ensure safety and access to prescription drugs. H.R. 2502, Comparative Effectiveness Research Act of 2009. Lobbied to ensure safety and access to prescription drugs. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs. HELP Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Comprehensive Health Reform Draft Bill. Lobbied Members of Congress to ensure safety and access to prescription drugs. Affordable Health Choices Act. Lobbied to ensure safety and access to prescription drugs.
NO BILL, Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. H.R. 1616, Early Treatment of HIV/AIDS. Lobbied members of Congress in support of early treatment of HIV/AIDS. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act.Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations.
S. 515 and H.R. 1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2009 · first_quarter · Q1
NO BILL, Medicare Part D Oversight. Lobbied Members of Congress to educate on the benefits of private negotiation in Medicare Part D. S. 547, Drug Rebate Equalization Act. Lobbied against extending the Medicaid rebate to managed care organizations. H.R. 684 and S. 330, Medicare Prescription Drug Savings and Choice Act. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. H.R. 574 and S. 254, the Medicare Home Infusion Therapy Coverage Act. Lobbied for passage of the bill. H.R.1458/ S.565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007. Lobbied for passage of bills. H.R. 684/ S. 330, Medicare Prescription Drug Savings and Choice Act of 2009. Lobbied against establishing a government sponsored fall-back plan in Medicare Part D. 4S. 301, Physician Payments Sunshine Act of 2009. Lobbied to ensure access to prescription drugs.
H.R.1, American Recovery and Reinvestment Act. Lobbied to include language encouraging clinical comparative effectiveness rather than cost effectiveness. NO BILL, Health Care Reform. Lobbied to gather information on potential legislation to improve the health care system and increase access to prescription drugs. H.R. 1548, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. S. 525 and H.R. 1298, Pharmaceutical Market Access and Drug Safety Act. Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 1105, making appropriations for Fiscal Year 2009. Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. H.R. 759, Food and Drug Administration Globalization Act of 2009. Lobbied to ensure safety and access to prescription drugs H.R. 1427/ S. 726, Promoting Innovation and Access to Life-Saving Medicine Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 1298/ S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Lobbied to ensure safety and access to prescription drugs.
S. 515 and H.R.1260, Patent Reform Act of 2009. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages. H.R. 1706, Protecting Consumer Access to Generic Drugs Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs. S. 369, Preserve Access to Affordable Generics Act. Lobbied Members of Congress to protect access to safe and affordable prescription drugs.
NO BILL Tax Reform. Lobbied to gather information on potential legislation regarding deferral of foreign income.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2008 · third_quarter · 3A
H.R. 5629/S. 1695 Biologics Price Constitution & Innovation Act. Lobbied in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424 The Paul Wellstone Mental Health and Addiction Equality Act. Lobbied in support of mental health parity and against increased Medicaid rebates. Labor/HHS Appropriations Bill. Lobbied to ensure patient access to HIV/AIDS medicines through ADAP. S. 2731/H.R. 5501 Tom Lanthos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act. Lobbied in support of reauthorization of the President's Emergency Program for AIDS Relief. H.R. 5839 Safeguarding America's Pharmaceuticals Act. Lobbied to educate about the safety of the prescription drug supply chain. H.R. 3610 Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs. S. 999 The STOP Stroke Act. Lobbied for passage of bill. NO BILL, Pharmaceuticals in the environment. Lobbied to educate on the issue of pharmaceuticals in the environment.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2008 · fourth_quarter · Q4
S. 1145, Patent Reform Act of 2007. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages.
H.R. 5629/S. 1695, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424, The Paul Wellstone Mental Health and Addiction Equity Act.Lobbied Members of Congress in support of mental health parity and against increased Medicaid rebates. S. 2731/ H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008. Lobbied Members of Congress in support of reauthorization of the Presidents Emergency Program for AIDS Relief. H.R. 5839, Safeguarding America's Pharmaceuticals Act. Lobbied to educate Members of Congress about safety of the prescription drug supply chain. H.R. 3610, Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs. S. 999, The STOP Stroke Act. Lobbied for passage of bill. NO BILL, Pharmaceuticals in The environment. Lobbied to educate Members of Congress on the issue of pharmaceuticals in the environment. H.R.3043, Labor, HHS Appropriations Bill. Lobbied to ensure patient access to HIV/AIDS medicines through ADAP.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2008 · third_quarter · Q3
S. 1145, Patent Reform Act of 2007. Lobbied Members of Congress to improve provisions related to inequitable conduct and damages.
NO BILL, Cancer Research. Lobbied to support cancer research.
H.R. 5629/S. 1695, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424, The Paul Wellstone Mental Health and Addiction Equity Act. Lobbied Members of Congress in support of mental health parity and against increased Medicaid rebates. Labor, HHS Appropriations Bill. Lobbied to ensure patient access to HIV/AIDS medicines through ADAP S. 2731/ H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act. Lobbied Members of Congress in support of reauthorization of the Presidents Emergency Program for AIDS Relief. H.R. 5839, Safeguarding America's Pharmaceuticals Act. Lobbied to educate Members of Congress about safety of the prescription drug supply chain. H.R. 3610, Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs S. 999, The STOP Stroke Act. Lobbied for passage of bill. NO BILL, Pharmaceuticals in The environment. Lobbied to educate Members of Congress on the issue of pharmaceuticals in the environment.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2008 · second_quarter · Q2
NO Bill Number, Cancer Research. Lobbied to support cancer research.
H.R. 5629/S. 1695, Biologics Price Competition & Innovation Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424, The Paul Wellstone Mental Health and Addiction Equity Act. Lobbied Members of Congress in support of mental health parity and against increased Medicaid rebates. S. 2731/ H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008. Lobbied Members of Congress in support of reauthorization of the Presidents Emergency Program for AIDS Relief. H.R. 5629/ S. 1695, Pathway for Biosimilars Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety and data exclusivity. H.R. 3610, Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs S. 999, The STOP Stroke Act. Lobbied for passage of bill H.R. 5839, Safeguarding Americas Pharmaceuticals Act of 2008. Lobbied for passage of bill. S. 2320 NO Bill Number, Pharmaceuticals in The environment. Lobbied to educate Members of Congress on the issue of pharmaceuticals in the environment. No Bill Number, Labor, HHS Appropriations Bill. Lobbied to ensure patient access to HIV/AIDS medicines through ADAP.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2008 · first_quarter · Q1
H.R. 5629, Pathway for Biosimilars Act. Lobbied Members of Congress in support of an FDA pathway for biosimilar products, patient safety, and data exclusivity. H.R. 1424, The Paul Wellstone Mental Health and Addiction Equity Act. Lobbied Members of Congress in support of mental health parity and against increased Medicaid rebates. S. 2731/ H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008. Lobbied Members of Congress in support of reauthorization of the Presidents Emergency Program for AIDS Relief. S. 558, Mental Health Parity Act. Lobbied Members of Congress in support of mental health parity and against increased Medicaid rebates. H.R. 1038/S. 623, Access to Life-Saving Medicine Act. Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. H.R. 1956, Patient Protection and Innovative Biologic Medicines Act. Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. H.R. 5629, Pathway for Biosimilars Act. Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. S. 1505, Affordable Biologics for Consumers Act. Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. H.R. 3610, Food and Drug Import Safety Act of 2007. Lobbied to ensure safety and access to prescription drugs. S. 999, The STOP Stroke Act. Lobbied for passage of bill. Labor, HHS Appropriations bill(No Bill Number Yet). Lobbied to ensure patient access to HIV drugs through the ADAP program.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2007 · mid_year · MA
HR.2419: The Farm, Nutrition, and Bioenergy Act. Lobbied for inclusion of more fruits and vegetables in school lunch program. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for the fiscal year ending September 30, 2008, and for other purposes. Lobbied for inclusion of more fruits and vegetables in school lunch program.
H.R. 2900/ S 1082:Food and Drug Administration Amendments. Lobbied for adequate funding for FDA and related issues. H.R.2589: Improving Pharmaceuticals for Children Act. Lobbied for passage of bill. HR 1038/ HR 1956/S 623/ S 1659: To create a pathway for FDA to approve follow-on biologic drugs. Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. S 1710: Labor, HHS Appropriations bill. Lobbied to ensure patient access to HIV drugs through the ADAP program. HR 380/S 242:Pharmaceutical Market Access and Drug Safety Act. Lobbied to protect patient safety of prescription drugs. S 1342: Healthy Lifestyles and Prevention America Act. 'HeLP America Act'. Lobbied for inclusion of more fruits and vegetables in school lunch program. HR 2144: Farm, Nutrition, and Community Investment Act of 2007. Lobbied for inclusion of more fruits and vegetables in school lunch program. H. Res. 433/ S. Res 221: Supporting the goals and ideals of National Peripheral Arterial Disease Awareness Month. Lobbied for passage of resolutions. H.R.583/S.1042: Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2007. Lobbied for passage of bills.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2007 · year_end · YA
H.R. 4/ S. 3, Medicare Prescription Drug Price Negotiation Act of 2007, Lobbied to maintain private sector negotiations in the Medicare drug benefit. H.R. 3963, SCHIP Extension Bill,Lobbied to maintain safety and access to prescription drugs. H.R.1293/S. 1338, Access to Medicare Imaging Act of 2007, Lobbied for passage of bills. H.R. 2058/S. 1103, Helping Fill the Medicare Rx Gap Act, Lobbied to enhance patient access to Medicare Part D drugs H.R. 1845/S. 1428, Medicare Durable Medical Equipment Access Act, Lobbied to ensure patient access to Medicare durable medical equipment - ostomy and wound care services. Medicare Coverage Policy for Wound Care, Lobbied to ensure patient access to timely and appropriate treatment options. Home Health Prospective Payment System, Lobbied to ensure patient access to ostomy services. Medicaid Rebate Policy, Lobbied to ensure proper payment of rebates.
S. Con. Res. 21, Establishing the Congressional budget for the U.S. Government for FY 2008 and including the appropriate budgetary levels for FY 2007 and 2009-2012, Lobbied to ensure safety and access to prescription drugs. S. 1751, An original bill making appropriations for energy and water development for the fiscal year ending September 30, 2008, and for other purposes, Lobbied to restore $25 million in funding for nuclear medicine research. H.R. 2764, Omnibus Appropriations Bill, Lobbied to maintain safety and access to prescription drugs. H.R. 1591/S. 965, Supplemental Appropriations bill, Lobbied to maintain the current Medicaid rebate percentage.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2007 · year_end · YY
H.R. 2419, Farm Bill Extension Act of 2007, Lobbied for inclusion of more fruits and vegetables in school lunch program. S. 2302, The Food and Energy Security Act of 2007, Lobbied for inclusion of more fruits and vegetables in school lunch program.
S. Con. Res. 21, Establishing the Congressional budget for the U.S. Government for FY 2008 and including the appropriate budgetary levels for FY 2007 and 2009-2012, Lobbied to ensure safety and access to prescription drugs.
H.R.3966 Tax Increase Prevention Act of 2007, Lobbied to achieve an extension of the Research and Development Tax Audit.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2007 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2006 · year_end · YY
H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied again signing a discharge petition to bring this bill to a floor vote. H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding. H.R.4939, Emergency Supplemental Appropriations Act of Defense, the Global War on Terror, and Hurricane Recovery of 2006, Lobbied to preserve the market based Medicare Part D Rx drug Benefit. H.R.5704, Access to Medicare Imaging Act, Lobbied for passage of the bill, which would provide for a budget neutral two-year moratorium on Medicare payment reductions for imaging services. H.Con.Res.373, Establishing the congressional budget for the United States Government for fiscal year 2007, Lobbied to preserve the Medicare Part D drug benefit.
S.4026, Technical Tax Corrections Act of 2006, lobbied to amend the IRS Section 170 definition of income purposes of charitable contributions. H.R.6111, Tax Relief Extension Reconciliation Act of 2006, Lobbied to extend the research and development tax credit. H.R.6264, Technical Tax Corrections Act of 2006, lobbied to amend the IRS Section 170 definition of income purposes of charitable deductions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2006 · mid_year · MM
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding. H.R.4939, Emergency Supplemental Appropriations Act of Defense, the Global War on Terror, and Hurricane Recovery, 2006, Lobbied to preserve the market based Medicare Part D Rx drug benefit.H.Con.Res.373, Establishing the congressional budget for the United States Government for fiscal year 2007, Lobbied to preserve the Medicare Part D drug benefit. H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2005 · year_end · YY
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs.
H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote. H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding.
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2005 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · RA
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2002 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2002 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · year_end · YA
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · year_end · YY
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
1999 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
S. 1145 Patent Reform Act of 2007. Lobbied to improve provisions related to inequitable conduct and damages.
NO BILL, Cancer Research. Lobbied in support of cancer research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Panama, Columbia, and Peru Free Trade Agreements. Lobbied to ensure fair patent protections in trade agreements. HR 1908/S 1145: Patent Reform Act. Lobbied to ensure fair patent protections for pharmaceuticals.
Panama, Columbia, and Peru Free Trade Agreements. Lobbied to ensure fair patent protections in trade agreements Philippine Infant Formula Issue. Lobbied to ensure continued access to infant formula in the Philippines. KORUS Free Trade Agreements. Lobbied to ensure intellectual property protection for innovative product, fair and transparent pricing and reimbursement processes.
HR 976: Small Business Tax Relief Act. Lobbied to support favorable provisions of the tax code. HR 1712: R&D Tax Credit. Lobbied to make permanent the tax credit.
S. Con. Res. 21- Establishing the Congressional budget for the U.S. Government for FY 2008 and including the appropriate budgetary levels for FY 2007 and 2009-2012. Lobbied to ensure safety and access to prescription drugs. S.1751: An original bill making appropriations for energy and water development for the fiscal year ending September 30, 2008, and for other purposes. Lobbied to restore $25 million in funding for nuclear medicine research. HR 1591/ S 965: Supplemental Appropriations bill. Lobbied to maintain the current Medicaid rebate percentage.
HR 4/ S 3: Medicare Prescription Drug Price Negotiation Act of 2007. Lobbied to maintain the private sector negotiations in the Medicare drug benefit. HR 2058/S.1103: Helping Fill the Medicare Rx Gap Act. Lobbied to enhance patient access to Medicare Part D drugs. H.R.1293/S. 1338-Access to Medicare Imaging Act of 2007. Lobbied for passage of bills. HR 1845/S 1428 Medicare Durable Medical Equipment Access Act. Lobbied to ensure patient access to Medicare durable medical equipment - ostomy and wound care services. Medicare Coverage Policy for Wound Care. Lobbied to ensure patient access to timely and appropriate treatment options. Home Health Prospective Payment System. Lobbied to ensure patient access to ostomy services.
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R.3966 Tax Increase Prevention Act of 2007, Lobbied to achieve an extension of the Research and Development Tax Audit.
H.R. 2900, Food and Drug Administration Amendments, Lobbied for adequate funding for FDA and related issues. S. 1082, Prescription Drug User Fee Amendments of 2007, Lobbied for adequate funding for FDA and related issues. H. Res. 433, Supporting the goals and ideals of National Peripheral Arterial Disease Awareness Month, Lobbied for passage of resolution. S. Res. 221, A resolution supporting National Peripheral Arterial Disease Awareness Month and efforts to educate people about peripheral arterial disease, Lobbied for passage of resolution. H.R. 583/S. 1042, Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2007, Lobbied for passage of bills. H.R. 380/S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, Lobbied to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes, to ensure safety of drugs and access for patients. H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. H.R. 1038/S. 623, Access to Life-Saving Medicine Act,Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. S.1505, Affordable Biologics for Consumers Act, Lobbied to protect incentives to innovate new biologic drugs and to ensure appropriate safeguards for follow-ons. H.R. 3610, Food and Drug Import Safety Act of 2007, Lobbied to ensure safety and access to prescription drugs S. 999, The STOP Stroke Act, Lobbied for passage of bill. H.R. 2589, Improving Pharmaceuticals for Children Act, Lobbied for passage of bill. S. 1082, Prescription Drug User Fee Amendments of 2007, Lobbied for adequate funding for FDA and related issues. H.R. 3610, Food and Drug Import Safety Act of 2007, Lobbied to ensure safety and access to prescription drugs. H.R. 1585, Defense Authorization Bill, Lobbied to maintain safety and access to prescription drugs. S. 1710, Labor, HHS Appropriations bill, Lobbied to ensure patient access to HIV drugs through the ADAP program.
H.R. 1908/S. 1145, Patent Reform Act, Lobbied to ensure fair patent protections for pharmaceuticals.
H.R. 2419, Farm Bill Extension Act of 2007, Lobbied for inclusion of more fruits and vegetables in school lunch program. S. 2302, The Food and Energy Security Act of 2007, Lobbied for inclusion of more fruits and vegetables in school lunch program.
U.S./Korea Free Trade Agreement, Lobbied to achieve greater protection for Intellectual property rights. Columbia/Panama/Peru Free Trade Agreement, Lobbied to achieve greater protection for Intellectual property rights. Turkey/Data Protection, Lobbied to ensure compliance with international obligations and national law regarding data protection Poland/Reimbursement of Innovative Medicines, Lobbied to ensure Polands compliance to its obligation to conduct a transparent and equitable reimbursement procedure. Thailand/Compulsory Licensing, Lobbied to achieve protection of intellectual property for innovative product Philippines/Ban on Advertising and Marketing, Lobbied to ensure compliance with laws allowing advertising and marketing of infant formulas. Vietnam/restrictions on representative offices, Lobbied to prevent restrictive actions on the part of Vietnamese government.
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 1908/S. 1145, Patent Reform Act, Lobbied to ensure fair patent protections for pharmaceuticals.
H.R. 4/ S. 3, Medicare Prescription Drug Price Negotiation Act of 2007, Lobbied to maintain private sector negotiations in the Medicare drug benefit.
H.R. 2900, Food and Drug Administration Amendments, Lobbied for adequate funding for FDA and related issues. S. 1082, Prescription Drug User Fee Amendments of 2007, Lobbied for adequate funding for FDA and related issues.
U.S./Korea Free Trade Agreement, Lobbied to achieve greater protection for Intellectual property rights. Columbia/Panama/Peru Free Trade Agreement, Lobbied to achieve greater protection for Intellectual property rights.
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Lobbied against an amendment to remove language from the MMA prohibiting IHS from interfacing in negotiations for the drug benefit. H.R.5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R.5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Res.100, Continuing Resolutions for 2007 Appropriations, Lobbied to ensure adequate funding of healthcare programs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011.
S.2300, Federal Food Drug & Cosmetic Act, Lobbied to preserve exclusivity of innovative prescription drugs. H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007,Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues.
Lobbied to prevent provisions adverse to prescription drug approval process.H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870, Federal Food, Drug and Cosmetic Act, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R.4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R.3559, Medicare DME Access Act, Lobbied to ensure access to medical devices and DME services. H.R. 6143, Ryan White Care Act Reauthorization, Lobbied to ensure safe access to prescription drugs. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.2300, Lower Priced Drugs Act of 2006, Lobbied to preserve incentives for R&D for pediatric populations. S.3558, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. S.3650, Helping Fill the Medicare Rx Gap Act, Lobbied to ensure safe access to prescription drugs. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children. S.Res 556, Lobbied to raise awareness of P.A.D. and for passage of the bill. H.Res 982, Lobbied to raise awareness of P.A.D. and for passage of the bill. H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005.
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R.3025, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, Lobbied for final passage of the bill. H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R.5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs.
H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1783, R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit. H.R.2830R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit.
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007, Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues. S.2300, Federal Food, Drug and Cosmetic Act, Lobbied to preserve the exclusivity of innovative prescription drugs.
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
H.Con.Res.95, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2007 through 2010. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006. Lobbied to ensure safety of prescription drugs. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program.
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE